SIR,-It has been my practice for a number of years to treat inoperable ovarian carcinoma with thiotepa (triethylene thiophosphoramide). I introduce 45 mg. in saline into the peritoneal cavity at the time of operation and subsequently give 300 mg. in divided doses intramuscularly, checking on the white cell count before each dose. Apart from leucopenia, I have never heard of any untoward side-effects until recently, although several patients have declared that the therapy made them feel extremely ill. My most recent case, however, has lost a good deal of hair. Alopecia as the result of treatment with Endoxana (cyclophosphamide) is well known, of course, but I have not met it before with thiotepa. I would be interested to know if any of your readers have met this complication and whether it is something we must expect occasionally.-I am, etc., Manchester 3. WALTER CALVERT.

No abstract

No abstract

No abstract

No abstract